ストックスクリーナーアプリを入手
71.54
1.50%
1.06
前日終値:
$70.48
開ける：
$71.05
24時間の取引高:
2.78M
Relative Volume:
0.50
時価総額：
$27.61B
収益：
$4.82B
当期純損益:
$930.40M
株価収益率:
30.60
EPS:
2.3381
ネットキャッシュフロー:
$1.43B
1週間 パフォーマンス:
-6.67%
1か月 パフォーマンス:
+2.57%
6か月 パフォーマンス:
-1.81%
1年 パフォーマンス:
-17.52%
1日の値動き範囲:
$69.79
$71.85
1週間の範囲:
$69.79
$77.08
52週間の値動き範囲:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
71.54 | 27.61B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
103.06 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.25 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.21 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.25 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.63 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2026-01-12 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 開始されました | Evercore ISI | In-line |
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
Dexcom stock trades near recent highs as diabetes tech growth supports valuation - AD HOC NEWS
FDA selects Dexcom as first participant in TEMPO pilot for digital health devices - MedTech World
DexCom Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Dexcom Gets First Slot In FDA-CMS Pilot That Rewards Real-World Data At Scale - insights.citeline.com
FDA names Dexcom as first participant in digital health pilot - MedTech Dive
DexCom (DXCM) Earnings Expected to Grow: Should You Buy? - Yahoo Finance Singapore
Dexcom Kicks Off FDA’s TEMPO Digital Health Device Pilot - Medical Product Outsourcing
DXCM|Dexcom Inc|Price:70.480| - TradingKey
Dexcom (DXCM) Chosen as First Participant in FDA's TEMPO Pilot - GuruFocus
Dexcom stock trades near record levels as glucose monitoring demand supports growth - Ad-hoc-news.de
Dexcom (DXCM) Selected for FDA's TEMPO Pilot Program to Enhance Glucose Monitoring - GuruFocus
DexCom, Inc.'s Stock Price Drops to $71.43, Marking a 4.44% Decrease: Uncovering the Reasons Behind the Downfall - Smartkarma
A Look at DexCom Inc (DXCM) After 4.4% Decline -- GF Value $104.58 vs Price $71.43 - GuruFocus
A Look at DexCom Inc (DXCM) After 4.4% Decline -- GF Value $104. - GuruFocus
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program - Dexcom Investor Relations
DexCom Inc. stock underperforms Wednesday when compared to competitors - MSN
At US$74.75, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List? - Moomoo
Dexcom Selected as First Participant in FDA's TEMPO Pilot Program - Intellectia AI
Dexcom Executive Chair Kevin R. Sayer Disposes of 26,756 Shares via Prearranged Rule 10b5-1 Plan - Kalkine Media
Dexcom Inc (DXCM) chair Kevin Sayer sells 26,756 shares under 10b5-1 plan - Stock Titan
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
Dexcom stock trades near 52-week high as G7 CGM growth supports earnings momentum - AD HOC NEWS
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) executive plans 26,756-share stock sale - Stock Titan
Dexcom stock trades steady as diabetes CGM growth supports earnings outlook - Ad-hoc-news.de
Dexcom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MSN
Dexcom stock holds steady as investors weigh Q1 2026 growth - ad-hoc-news.de
Enterprise value to EBIT forward of DexCom, Inc. – FWB:DC4 - TradingView
DexCom (DXCM) Back In Focus As Canada Approval Tests Its Valuation - Sahm
Dexcom stock trades steady as diabetes technology growth supports valuation - ad-hoc-news.de
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom Inc. Stock Climbs 7.2%, Outperforms Market - webull.com
DXCM5813816 Bond Profile — Key Metrics - TradingView
Form 4 DexCom Inc For: 16 July By Investing.com - Investing.com Nigeria
Dexcom stock trades steady as CGM demand supports revenue growth - ad-hoc-news.de
Truist raises DexCom stock price target to $87 on growth outlook By Investing.com - Investing.com South Africa
Dexcom EVP chief legal compliance off sells $126,514 in stock By Investing.com - Investing.com Nigeria
DEXCOM INC : TRUIST SECURITIES RAISES TARGET PRICE TO $87 FROM $80 - Bitget
ETFs Investing in DexCom, Inc. Stocks - TradingView
DexCom Inc (DXCM) Stock Up 7.2% and Still Undervalued -- GF Scor - GuruFocus
Truist raises DexCom stock price target to $87 on growth outlook - Investing.com Nigeria
DexCom, Inc.’s stock price soars to $77.98, marking a remarkable 7.22% increase - Smartkarma
Dexcom EVP chief legal compliance off sells $126,514 in stock - Investing.com
DEXCOM INC (DXCM) EVP reports 1,700-share planned stock sale in Form 4 - Stock Titan
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Why DexCom (DXCM) Stock Is Up Today - Quiver Quantitative
Why DexCom Inc (DXCM) Is Set to Outperform the Market: Insights into Financial Growth and Competitive Advantage - GuruFocus
Truist Adjusts Price Target on DexCom to $87 From $80, Maintains Buy Rating - marketscreener.com
US252131AM9 Bond Profile — Key Metrics - TradingView
How Health Canada’s Longer-Wear CGM Approval At DexCom (DXCM) Has Changed Its Investment Story - simplywall.st
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
2.27%
0.54%
大文字化:
|
ボリューム (24 時間):